Biomarker ID | 1031 |
PMID | 23231923 |
Year | 2012 |
Biomarker | miR-30d |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Shorter Survival Time in High miRNA-30d group |
Odds Ratio/Hazard Ratio/Relative Risk | [Univariate: HR: 2.963 (95% CI: 1.052-8.342)]; [Multivariate: HR: 5.926 (95% CI: 1.748-20.094)] |
Effect on Pathways | Pathways Include:- transcription by RNA polymerase II; regulation of transcription by RNA polymerase II; Gene expression (Transcription); cellular protein modification process; protein modification process |
Experiment | Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | surgical specimens obtained during radical prostatectomy (n = 56) along with paired normal controls from the same patients. Patients were divided into two groups according to miRNA-30d expression. median miR- 30d expression level (high: ≥ 7.95 [arbitrary unit; a.u.], n = 28; low: < 7.95 [a.u.], n = 28), |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Biochemical recurrence was defined as continuous elevation with a PSA level > 0.2 ng/mL |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | miR-30d |